Disclosed here are diphenyl sulphide derivatives of general formula (I), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as sphingosine-1-phosphate 3 (S1P3) receptor-antagonists and as such are useful in the treatment or prevention of arterial sclerosis, blood vessel intimal hypertrophy, solid tumors, diabetic retinopathy, rheumatoid arthritis, cardiac arrest, ischemia-reperfusion disorders, cerebral blood vessel spasms after subarachnoid bleeding, angina pectoris or myocardial infarction caused by coronary vessel spasms, glomerulonephritis, thrombosis, lung disease caused by pulmonary edema, cardiac arrhythmia, eye disease, eye hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macula-lutea degeneration or sepsis. Examples of particularly preferred compounds include: (S)-2-amino-4-[2-chloro-4-(2-hydroxy-5-trifluoromethylphenylthio)phenyl]-2-propylbutylphosphoric acid monoester, (R)-2-allyl-2-amino-4-[2-chloro-4-(2-hydroxy-5-trifluoromethylphenylthio)phenyl]butylphosphoric acid monoester, (S)-2-amino-4-[2-chloro-4-(2-hydroxy-5-trifluoromethylphenylthio)phenyl]-2-methylbutylphosphoric acid monoester, (-)-2-amino-4-[2-chloro-4-(2-hydroxy-5-trifluoromethylphenylthio)phenyl]-2-propylbutylphosphoric acid monoester, (-)-2-amino-4-[2-chloro-4-(2-hydroxy-5-trifluoromethylphenylthio)phenyl]-2-methylbutylphosphoric acid monoester, (-)-2-amino-4-[4-(5-benzyloxy-2-hydroxyphenylthio)-2-chlorophenyl]-2-propylbutylphosphoric acid monoester.
